Ads
related to: new drugs for hepatitis c
Search results
Results from the WOW.Com Content Network
Glecaprevir (INN, [1]) is a hepatitis C virus (HCV) nonstructural (NS) protein 3/4A protease inhibitor that was identified jointly by AbbVie and Enanta Pharmaceuticals. [2] It is being developed as a treatment of chronic hepatitis C infection in co-formulation with an HCV NS5A inhibitor pibrentasvir.
Sofosbuvir is also used with other medications and longer treatment durations, depending on specific circumstances, genotype and cost-effectiveness–based perspective. For example, for the treatment of genotypes 1, 4, 5, and 6 hepatitis C infections, sofosbuvir can be used in combination with the viral NS5A inhibitor ledipasvir. [16]
Sofosbuvir/velpatasvir, sold under the brand name Epclusa among others, is a fixed-dose combination medication for the treatment of hepatitis C in adults. [2] [5] [6] [7] It combines sofosbuvir and velpatasvir. [2] [5] [6] It is more than 90% effective for hepatitis C genotypes one through six. [2]
A liver disease caused by the hepatitis C virus (HCV), viral hepatitis is the leading cause of liver cancer and the most Achillion's 'Very Promising' New Drug for Hepatitis C Skip to main content
For a decade now, the world has had highly effective medications for hepatitis C infections. In the United States, they’ve mostly been sitting on the shelf, according to a new study.
Johnson & Johnson announced priority review for its hepatitis C drug simeprevir. In this video, health-care analyst David Williamson discusses the positive aspects of this decision and how a ...
Ads
related to: new drugs for hepatitis c